Post-cardioversion atrial stunning: What do we need to know?;Lo stunning atriale postcardioversione: Cosa e importante conoscere?

Giornale Italiano di Cardiologia

Volumn 28, Issue 10, 1998, Pages 1162-1165

  Carerj, Scipione ^a,b   Adornato, Elena Maria Fernanda ^a  

^a UNIVERSITY OF MESSINA   (Italy)

^b NONE   (Italy)

Author keywords

Atrial stunning

Indexed keywords

CARDIOVERSION; HEART ATRIUM MUSCLE; HUMAN; REVIEW; STUNNED HEART MUSCLE; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; TRANSTHORACIC ECHOCARDIOGRAPHY;

ATRIAL FIBRILLATION; ELECTRIC COUNTERSHOCK; HEART ATRIA; HUMANS; MYOCARDIAL STUNNING;

EID: 0031789521     PISSN: 00465968     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (22)

1. FATKIN D, KUCHAR DL, THORBURN CW, FENELEY MP: Transesophageal echocardiography before and during direct current cardioversion of atrial fibrillation: evidence for "atrial stunning" as a mechanism of thromboembolic complications. J Am Coll Cardiol 1994; 23: 307-316.
2. GRIMM RA, STEWART WJ, MALONEY JD, ET AL: Impact of electrical cardioversion of atrial fibrillation on left appendage function and smoke: characterization by simultaneous transesophageal echocardiography. J Am Coll Cardiol 1993; 22: 1359-1366.
3. TABATA T, OKI T, IUCHI A, ET AL: Evaluation of left atrial appendage function by measurement of changes in flow velocity patterns after electrical cardioversion in patients with isolated atrial fibrillation. Am J Cardiol 1997; 79: 615-620.
4. IRANI WN, GRAYBURN PA, AFRIDI I: Prevalence of thrombus, spontaneous echo contrast, and atrial stunning in patients undergoing cardioversion of atrial flutter. Circulation 1997; 95: 962-966.
5. BLACK IW, FATKIN D, SAGAR KB, ET AL: Exclusion of atrial thrombus by transesophageal echocardiography does not preclude embolism after cardioversion of atrial fibrillation. A multicenter study. Circulation 1994; 89: 2509-2513.
6. MANNING WJ, SILVERMAN DI, KEIGHLEY CS, OETTGEN P, DOUGLAS PS: Transesopahageal echocardiographically facilitated early cardioversion from atrial fibrillation using short-term anticoagulation: final results of a prospective 4.5-yer study. J Am Coll Cardiol 1995; 25: 1354-1361.
7. MANNING WJ, SILVERMAN DI, KATZ SE, ET AL: Temporal dependence of the return of atrial mechanical function on the mode of cardioversion of atrial fibrillation to sinus rhythm. Am J Cardiol 1995; 75: 624-626.
8. OMRAN H, JUNG W, RABAHIEH R, ET AL: Left atrial chamber and appendage function after internal atrial defibrillation: a prospective and serial transesophageal echocardiographic study. J Am Coll Cardiol 1997; 29: 131-138.
9. DAOUD EG, KNIGHT BP, WEISS R, ET AL: Atrial fibrillation-induced acute atrial mechanical dysfunction in humans (abstract). Circulation 1997; 96 (Suppl I): I-453.
10. FALCONE RA, MORADY F, ARMSTRONG WF: Transesophageal echocardiographic evaluation of left atrial appendage function and spontaneous contrast formation after chemical or electrical cardioversion of atrial fibrillation. Am J Cardiol 1996; 78: 435-439.
11. MANNING WJ, SILVERMAN DI, KATZ SE, ET AL: Impaired left atrial mechanical function after cardioversion: relation to the duration of atrial fibrillation. J Am Coll Cardiol 1994; 23: 1535-1540.
12. BELLANDI F, DABIZZI RP, MUGNAIONI G, CANTINI F, PALCHETTI R: Chemical cardioversion of lone atrial fibrillation: recovery of atrial mechanical function and relation to duration of arrhythmia. G Ital Cardiol 1997; 27: 1029-1035.
13. POLLAK A, FALK RH: Aggravation of postcardioversion atrial dysfunction by sotalol. J Am Coll Cardiol 1995; 25: 665-671.
14. KLEIN AL, GRIMM RA, BLACK IW ET AL: Return of atrial function postcardioversion: comparison between left atrial appendage and left atrial cavity function by doppler transesophageal echocardiography (abstract). J Am Coll Cardiol 1993; 21: (suppl A): 28A.
15. OLTRONA L, BROCCOLINO M, MERLINI PA, SPINOLA A, PEZZANO A, MANNUCCI PM: Activation of the hemostatic mechanism after pharmacological cardioversion of acute nonvalvular atrial fibrillation. Circulation 1997; 95: 2003-2006.
16. UNO M, TSUJI H, SAWADA S, TOYODA T, NAKAGAWA M: Fibrinopeptide A (FPA) level in atrial fibrillation and effect of heparin administration. Jpn Circ J 1988; 52: 9-12.
17. GUSTAFSSON C, BLOMBACK M, BRITTON M, HAMSTEN A, SVENSSON J: Coagulation factors and the increased risk of stroke in nonvalvular atrial fibrillation. Stroke 1990; 21: 47-51.
18. YAMAGUCHI K, FURUI H, TANIGUCHI N, SOTOBATA I: Plasma β-thromboglobulin and platelet factor 4 concentrations in patients with atrial fibrillation. Jpn Heart J 1986; 27: 481-487.
19. ASAKURA H, HIFUMI S, JOKAJI H, ET AL: Prothrombin fragment F1 + 2 and thrombin-antithrombin III complex are useful remarkers of the hypercoagulative state in atrial fibbrillation. Blood Coagul Fibrinolysis 1992; 3: 469-473.
20. LIP GY, DUNN FG: Fibrinogen and fibrin D-dimer levels in paroxysmal atrial fibrillation: evidence for intermediate elevated levels of intravascular thrombogenesis. Am Heart J 1996; 131: 724-730.
21. AMERICAN COLLEGE OF CHEST PHYSICIANS: Third American College of Chest Physicians Conference on Antithrombotic Therapy. Chest 1992; 102: 303S-305S.
22. OMRAN H, JUNG W, WIRTZ P, SCHIMPF R, ILLIEN S, LUDERITZ B: Assessment of left atrial appendage function and detection of thrombi: a prospective study comparing transthoracic and transesophageal echocardiography (abstract). Circulation 1997; 96 (Suppl I): I-25.